Welcome to the August Edition of our See The Bigger Picture monthly newsletter, which keeps you up to speed on the latest developments within the Tr’I’fecta: Immuno oncology (IO), imaging, and ImaginAb.

In our first edition exclusively available through our Knowledge Hub, we discuss results from our ‘What Pharma Wants’ survey – where we interviewed Pharmaceutical and Biotech companies to understand challenges in IO clinical trials and how they would use 89Zr cefmirlimab berdoxam (CD8 ImmunoPET). CD8 ImmunoPET is investigational and has not yet received market authorization in any geography.

Click to learn the top 6 issues pharma wants to address in IO clinical trials.

What’s in this edition:

Main Feature: What Pharma Wants... how might one achieve a comprehensive CD8 status of tumors in IO clinical trials?

Advancements in IO
- Article - Rethinking the immunotherapy numbers game to improve predictive response
- Article - FDA Oncology Center of Excellence projects seek to advance the design of oncology trials

Advancements in ImaginAb
- Announcing new ‘What Pharma Wants’ survey data, what matters most to pharmaceutical companies in their immune-oncology (IO) clinical trials
- UC Davis uses ImaginAb’s 89Zr cefmirlimab berdoxam in new research showing how total-body PET imaging can assess the immunological response to Covid-19 infections

Upcoming Events
- ESMO 2022, schedule a meeting to get the first look at new CD8 ImmunoPET images in Paris
- Ian Wilson, CEO joins the panel with DC Pharma at BioAroundWorld
- Alessandro Masconi, Director of Research, facilitates Target Selection discussion at the West Coast Antibody Therapeutics Xchange

What Pharma Wants...
How might one achieve a comprehensive CD8 status of tumors in IO clinical trials?

"Gold standard" traditional needle biopsies provide a microscopic picture within a single tumor. Unfortunately this method has inherent limitations (e.g. sampling error, repeat biopsy difficult).

Introducing CD8 ImmunoPET to the toolbelt of immunotherapy clinical trials may help clinicians better guide biopsies while also generating a full-body image of CD8 cells in all tumors. CD8 ImmunoPET may allow investigators to achieve a more comprehensive CD8 status on multiple tumors in a patient. The animated image illustrates how CD8 ImmunoPET may be able to capture CD8 activity in the whole body, which could be missed entirely in trials imaging with biopsy alone.

As illustrated by the before and after figures, the needle biopsy provides only a microscopic view of a single tumor, making it difficult to assess intra-tumor heterogeneity and impossible to develop an understanding of the inter-tumor heterogeneity within the same subject.
Do you experience any of these challenges with biopsy in your clinical trials? Let us know.

In contrast to biopsy, the illustrated figures on the right demonstrate CD8 ImmunoPET’s ability to generate whole body images, providing a macroscopic view of the entire subject which may allow drug developers to see heterogeneity within individual tumors and assess heterogeneity across multiple tumors in the same subject.

Based on the results of our Ph I and Ila clinical studies, we believe having CD8 information of the entire body, including all tumor and normal immune organs, may allow increased whole body understanding of drug efficacy versus a single biopsy alone.

Schedule a call with our team to start a conversation about CD8 ImmunoPET.

Advancements in IO

Here we've highlighted relevant IO news spotted by our team this month. Contact us to recommend news to be featured in our next edition.

Rethinking the immunotherapy numbers game

This article provides an interesting hypothesis on using ‘mathematical oncology' modeling to improve tumor response and render it predictable is presented in this article from Rebecca Bekker, Heiko Enderling et al. in JITC.

Discuss with our teammate Gregory Frank who has started the conversation on social media: See LinkedIn Post.

News from the FDA Oncology Center of Excellence

Read about Project Significant: Statistics in Cancer Trials to learn about ongoing virtual discussions in clinical trials.

“Further the design and analysis of cancer clinical trials with the goal to advance cancer therapies... pave a path for cancer patients to receive earlier access to products through more efficient clinical trial(s)...”

“Poorly characterized dose and schedule may lead to selection of a dose that provides more toxicity without additional efficacy...”

Read Project Optimus: Reforming the dose optimization and dose selection paradigm in oncology for the full project details. Ask our team about utilizing CD8 ImmunoPET to help understand dose optimization in your clinical trial.

Advancements for ImaginAb

Keep up to date on the latest news on our free, online Knowledge Hub - where you can view all our abstract presentations, webinars, publications, articles and more.

New Knowledge Hub Content, ‘What Pharma Wants’ Survey

Announcing our “What Pharma Wants” survey, available exclusively through a virtual or in-person discussion with our team.

At ImaginAb, we make a point to practice what we preach.

While we encourage the innovators in the IO industry to See The Bigger Picture in their clinical trials with our CD8 ImmunoPET tracer, we have taken a step back ourselves and asked those pharma companies to walk us through the bigger picture in their clinical development programs.

Earlier this year, we conducted a survey interviewing pharmaceutical companies about current challenges in IO clinical trials, how they might use our investigational tracer, how they are using our investigational tracer... and we learned exactly ‘What Pharma Wants’.

Visit our free, online Knowledge Hub for more information on the survey, and schedule a non-confidential discussion with our team.
UC Davis’s new research shows how total-body PET imaging can assess the immunological response to Covid-19 infections.

“In the reported study, patients recovering from COVID-19 infection received a low injection dose (~0.5 mCi) of 89Zr-labeled radiotracer [89Zr-Crefmirlimab-Berdoxam, or CD8 ImmunoPET] that targeted CD8+ T cells and underwent a uEXPLORER PET/CT scan at different time points... The total-body PET images revealed subtle differences between five recovering COVID-19 patients and three healthy volunteers. The exceptional image quality obtained using the uEXPLORER scanner confirmed CD8+ T cell deposition in the spleen, liver, bone marrow, lymph nodes, and tonsils, as well as differences in the clearance rate of the radiotracer from the blood...”

Read the full article Here.

Upcoming Events

MEET US AT ESMO 2022

Conference Attendance
Meet our team in Paris, September 9-13 for a first look at the top 6 challenges pharma face in clinical trials, and see all-new CD8 ImmunoPET images.

SCHEDULE A MEETING

The People Behind ImaginAb
BioAroundWorld, September 20th

Our CEO Ian Wilson joins the panel discussion with DC Pharma at the BioAroundWorld 2022 Event: “Cross-Border Healthcare Innovation & Partnership” on September 20th. The collaboration will help accelerate the clinical development and commercialization of innovative therapies to address unmet clinical needs in China. Register for the webinar Here.

Antibody Therapeutics Xchange, September 27th

Director of Research, Alessandro Masconi will be facilitating the discussion around Target Selection in-person, at the West Coast Antibody Therapeutics Xchange in San Francisco on September 27th, 2022. Alessandro oversees early-stage discovery and development of biologics, with particular emphasis to oncology indications. Click here for more information: https://www.linkedin.com/feed/update/urn:li:activity:6965079570442059777

Register Here: https://www.hub-xchange.com/antibody-therapeutics-xchange-west-coast-2022/#anchor1

We want to hear from You

Did you know ImaginAb’s CD8 ImmunoPET Tracer is also available in Australia?

If you run clinical trials in Australia, we would like to know.

Contact Mandeep Sehmi, our Director of Business Development, for a discussion on the benefits of using CD8 ImmunoPET in Australia.

Let us know how we did, how did you rate this publication? Please contact us at info@imaginab.com for comments and feedback on what content you would like to see next.

Thank you, and remember to share our See The Bigger Picture newsletter with your life science colleagues... next edition coming in September!

References